# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
China has approved AstraZeneca's Tagrisso (osimertinib) combined with pemetrexed and platinum-based chemotherapy for first-...
AstraZeneca's ADJUVANT BR.31 Phase 3 trial reveals Imfinzi didn't meet the primary endpoint for disease-free survival i...
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism i...
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its bloc...